Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 3/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21330645 | 0.83 | THRB (0.67) | THRBLMNAKDM4EMAPTNPSR1 | |
| SCHEMBL22397221 | 0.82 | THRB (0.41) | THRBKDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL29355127 | 0.82 | THRB (0.41) | THRBKDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL510359 | 0.81 | KDM4E (0.64) | THRBKDM4EMEN1KMT2ARAB9A | |
| SCHEMBL21801782 | 0.79 | SCN5A (0.40) | MEN1KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL1393658 | 0.78 | MAPT (0.52) | KDM4EMAPTL3MBTL1KCNH2SCN9A | |
| SCHEMBL3584036 | 0.77 | L3MBTL1 (0.47) | THRBKDM4EMEN1KMT2ARAB9A | |
| SCHEMBL8332212 | 0.77 | KDM4E (0.58) | THRBKDM4EMEN1KMT2AMAPT | |
| SCHEMBL5942714 | 0.77 | LTA4H (0.46) | THRBKDM4EMEN1KMT2AMAPT | |
| SCHEMBL16838789 | 0.77 | RAB9A (0.47) | THRBLMNAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602044-A1 | SUBSTITUTED 3,7-DIHYDRO-1 H-PURINE-2,6-DIONES AND USE THEREOF | invIOs GmbH (AT) | 2025-08-20 | — | — | EP | disclosed |
| CN-119301113-A | Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024133605-A1 | SUBSTITUTED 3,7-DIHYDRO-1 H-PURINE-2,6-DIONES AND USE THEREOF | INVIOS GMBH (AT) | 2024-06-27 | — | — | WO | disclosed |
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
| EP-4028403-B1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-11-22 | — | — | EP | disclosed |
| US-11814375-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-4028403-A1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-07-20 | — | — | EP | disclosed |
| WO-2012069856-A1 | ANTIMALARIAL COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069856-A1 | ANTIMALARIAL COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2012-05-31 | — | — | WO | disclosed |
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| EP-1858876-A2 | PYRIDINONE DERIVATIVES AGAINST MALARIA | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094799-A2 | PYRIDINONE DERIVATIVES AGAINST MALARIA | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814375-B2 | Heterocyclic compounds | CYP1B1, CYP1A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | THRB 3635/4885LMNA 43/4885KDM4E 2052/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | THRB 2635/4885LMNA 154/4885KDM4E 1570/4885 |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | G6PD, PNPO, PLPBP | THRB 3337/4885LMNA 2161/4885KDM4E 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.